US FDA May Be Shifting Its Thinking On Biosimilar Trials

 
• By Dave Wallace
  
Two recent examples are seen of fresh thinking from the FDA on biosimilar development. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from R&D